General Rheumatology&nbsp;&nbsp;&nbsp;

Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?

Are there any concerns with live vaccine innoculation and patients who are on denosumab?

How do you manage a patient with cervical cancer who has FDG uptake in bilateral ischial tuberosities with lytic areas on CT correlate, and also has a history suspicious for untreated polymyalgia rheumatica with chronic symptoms in the same anatomic locations?

Cervical cancer FIGO stage IIIC2. Bloodwork shows elevated ESR and CRP.

What is your approach to working up diarrhea in an immunocompromised patient?

How do you approach immunosuppression in patients with a positive Interferon Gamma Release Assay and prior intravesicular BCG treatment for bladder cancer?

Assuming no symptoms of TB, should patients be treated for latent TB prior to starting TNF inhibitors or other immunosuppressive agents?

Is there a concern for the potential of future congenital malformations in offspring when preservation of eggs and sperm is done AFTER cyclophosphamide treatment given that it is an alkylating agent?

How do you approach evaluation and management of arthralgia in a patient after CAR-T cell therapy?

What would be the main indications for opting for biosimilars over an original biologic, outside of insurance barriers?

Are there any instances where you would prefer a biosimilar rather than the reference product?

How do you approach the workup for a patient with persistently elevated inflammatory markers (CRP and ESR) whose history and exam do not point to a clear cause?

How do you interpret elevations in ESR and CRP in the setting of increased BMI?

What is the appropriate management of arthralgias associated with bosutinib?

Would you consider continuing a biologic for difficult to control autoimmune disease in a patient with a recent diagnosis of a surgically curable solid malignancy?

Would you favor the use of any particular biologics over others?

How do you manage psoriatic arthritis in patients who are planning to start treatment with checkpoint inhibitors for underlying malignancy?

Do you recommend routine use of Evusheld for pre-exposure prophylaxis for patients on immunosuppression?

Does treatment with B-cell depletion and/or negative anti-spike antibody status despite COVID mRNA vaccination influence your decision?

When a patient with a preexisting rheumatic disease and on immunotherapy begins to flare, how do you decide if this is an underlying rheumatic disease activity versus an immunotherapy related adverse event?

How do you decide if it may be safe to continue immunotherapy?

How are you timing the third dose of the COVID-19 mRNA vaccine in patients on rituximab?

Do you recommend shingles vaccine to all immunosuppressed patients under the age of 50 y.o.?

How do you handle hypogammaglobulinemia detected in patients prior to maintenance rituximab infusion?